Dysken M W, Katz R, Stallone F, Kuskowski M
Minneapolis Veterans Administration Medical Center, MN.
J Neuropsychiatry Clin Neurosci. 1989 Summer;1(3):249-52. doi: 10.1176/jnp.1.3.249.
Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD). Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.
奥拉西坦是一种最近合成的促智药，曾作为治疗多发性梗死性痴呆（MID）和原发性退行性痴呆（PDD）患者认知功能衰退的潜在药物进行试验。受试者为34名符合该研究入选标准的MID患者和39名PDD患者。重复测量方差分析显示，MID患者和PDD患者在词语流畅性方面均有显著改善。亲属对老年患者总体症状评估的总分显示，PDD患者有显著改善。然而，日常生活活动能力量表的平均得分显示，PDD患者有显著下降。
